NOVOMEDLINK™

This page contains information about Novo Nordisk products.

NovoLog® FlexPen®:
A dial-a-dose insulin pen
that is easy to put in the
hands of patients

NovoLog® FlexPen® is the #1-selling prefilled insulin
pen in the world1

NovoLog® FlexPen®

*Needles are sold separately and may require a prescription in some states.

FlexPen® offers many benefits

  • Teachable, learnable, usable
  • Offers accurate insulin delivery2
  • Discreet—fits neatly in your patient’s purse or pocket
  • Covered on more than 90% of managed care plans3 †
  • Patients who use FlexPen® may get 50% more insulin with each prescription (1,500 units in a box of 5 pens, compared to 1,000
    units in a vial)

†Managed care plans only. Does not include Medicaid and Medicare Part D. Multiple products within the same therapeutic class may be considered preferred and on the same tier.
Formulary status is subject to change.

NovoTwist®—introducing the first single-twist needle

  • “Just Twist” injection needle with a bayonet fitting
  • Less time-consuming for patients to attach
  • Audible and tactile confirmatory click
    for correct attachment
  • Available for 30G (8 mm) and 32G Tip (5 mm) needles
Just twist

NovoPen® Junior—fine-tune small doses with
half-unit dose increments

NovoPen® Junior

NovoLog® 3-mL PenFill® cartridges

PenFill®

NovoLog® FlexPen®, 3-mL PenFill® cartridge,† and 10-mL vial: stable in storage

stable in storage

‡3-mL PenFill® cartridge is available for NovoPen® Junior and NovoPen® 3.

§FlexPen® and PenFill® cartridges in use (opened) must NOT be stored in the refrigerator.

||Vials in use (opened) may be stored in the refrigerator.

NovoLog®—designed to take the heat

  • NovoLog® FlexPen® and NovoLog® in the 3-mL PenFill® cartridge and vial are stable at temperatures up to 86oF once in use (opened) and do not require refrigeration (PenFill® cartridges and FlexPen® should not be refrigerated once in use)
  • NovoLog® remains heat-stable in pumps at normal body temperature (up to 98.6°F)

Learn more about the benefits of insulin analogs and the Novo Nordisk heritage of innovation. Visit insulinnovations.com

Related Support

View eSeminar Get details on the various delivery systems and equipment available for NovoLog®.

View product demonstration Watch a step-by-step demonstration of how to use NovoLog® FlexPen®.

Up Next

Dosing system flexibility with NovoLog® in the pump

References:

  1. IMS Health Inc. IMS MIDAS (12 months ending March 2011).
  2. Pfützner A, Reimer T, Hohberg C, Frøkjær LPF, Jørgensen C. Prefilled insulin device with reduced injection force: patient perception and accuracy. Curr Med Res Opin. 2008;24(9):2545-2549.
  3. Data on file, Novo Nordisk, Inc., Princeton, NJ.

  1. NovoLog® (insulin aspart [rDNA origin] injection) Indications and Usage

    NovoLog® is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.

    NovoLog® Important Safety Information

    NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients.

    NovoLog® has a more rapid onset and shorter duration of action than regular human insulin. An injection of NovoLog® should be immediately followed by a meal within 5 to 10 minutes. Because of the short duration of action of NovoLog®, a longer-acting insulin also should be used in patients with type 1 diabetes and may be needed in patients with type 2 diabetes. When used in an external subcutaneous insulin infusion pump, NovoLog® should not be mixed with any other insulin or diluent. Hypoglycemia is the most common adverse effect of all insulin therapies, including NovoLog®. The timing of hypoglycemia usually reflects the time-action profile of the administered insulins.

    Any change of insulin dose should be made cautiously and only under medical supervision. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy. As with all insulin preparations, the time course of action of NovoLog® may vary in different individuals or at different times in the same individual and is dependent on many conditions, including injection site, local blood supply, temperature, and level of physical activity.

    Needles and NovoLog® FlexPen® must not be shared.

    NovoLog® has not been studied in children with type 2 diabetes or in children with type 1 diabetes under the age of two.

    Severe, life-threatening generalized allergy, including anaphylactic reaction, may occur with any insulin product, including NovoLog®. Adverse reactions observed with NovoLog® include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. Insulin, particularly when given intravenously or in settings of poor glycemic control, may cause hypokalemia. Like all insulins, NovoLog® requirements may be reduced in patients with renal impairment or hepatic impairment.

    Please click hereclick here for Prescribing Information.

FlexPen®, NovoLog®, NovoPen®, NovoTwist®, and PenFill® are registered trademarks of Novo Nordisk A/S.
NovoMedLink™ is a trademark of Novo Nordisk A/S.